Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2025)

Historic Receivables - Net for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $116.5 million.

  • BridgeBio Pharma's Receivables - Net changed N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.5 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 16967.45% up from last year.
  • Per BridgeBio Pharma's latest filing, its Receivables - Net stood at $116.5 million for Q3 2025.
  • BridgeBio Pharma's 5-year Receivables - Net high stood at $116.5 million for Q3 2025, and its period low was $1.2 million during Q2 2021.
  • For the 4-year period, BridgeBio Pharma's Receivables - Net averaged around $52.7 million, with its median value being $40.8 million (2024).
  • The largest annual percentage gain for BridgeBio Pharma's Receivables - Net in the last 5 years was 16967.45% (2024), contrasted with its biggest fall of 16967.45% (2024).
  • Over the past 4 years, BridgeBio Pharma's Receivables - Net (Quarter) stood at $1.2 million in 2021, then soared by 44.35% to $1.8 million in 2023, then skyrocketed by 169.67% to $4.7 million in 2024, then soared by 2367.56% to $116.5 million in 2025.
  • Its last three reported values are $116.5 million in Q3 2025, $76.9 million for Q2 2025, and $115.3 million during Q1 2025.